NCT02204085 2026-04-03
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
Clinical Trials
117 trialsNCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT03358719 2026-02-27
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT03019003 2025-09-16
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Massachusetts General Hospital
Phase 1 Completed
NCT02269280 2025-08-07
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02257138 2025-06-08
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT03063944 2025-05-15
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
Thomas Jefferson University
Phase 1 Completed
NCT04277442 2025-03-25
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT02488408 2024-12-19
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
BerGenBio ASA
Phase 1/2 Completed
NCT02085408 2024-12-13
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT02664181 2024-09-03
PRECISE
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02103478 2024-08-27
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT03306264 2024-08-27
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT00042003 2024-08-02
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT00043381 2024-08-02
Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT03813186 2024-08-02
Effect of Food on Blood Levels of ASTX727
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT02632721 2024-03-19
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Boehringer Ingelheim
Phase 1/2 Completed
NCT02441803 2024-02-22
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01812252 2024-02-15
ICT-HCT
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT04055844 2023-11-07
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT02073838 2023-09-29
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Jewish General Hospital
Phase 2 Completed
NCT02959164 2023-07-28
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
University of Iowa
Phase 1 Completed
NCT04146038 2023-05-24
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT03941964 2023-03-20
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie
Phase 3 Completed
NCT01420926 2023-02-28
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT03303339 2023-02-27
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Cardiff Oncology
Phase 1/2 Completed
NCT02996474 2022-12-28
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT01834248 2022-07-22
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT02109744 2022-07-05
AML
University of Rochester
Phase 1/2 Completed
NCT01303796 2022-06-22
SEAMLESS
Cyclacel Pharmaceuticals, Inc.
Phase 3 Completed
NCT01893320 2022-02-09
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02190695 2021-05-19
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Fox Chase Cancer Center
Phase 2 Completed
NCT01720225 2020-12-24
Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01786343 2020-04-15
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02252107 2020-03-19
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
Radboud University Medical Center
Phase 2 Completed
NCT02921061 2020-03-17
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02316964 2020-03-09
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01546038 2020-03-03
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Pfizer
Phase 2 Completed
NCT01707004 2019-11-21
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Wisconsin, Madison
Phase 2 Completed
NCT01829503 2019-11-14
Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
University of Pittsburgh
Phase 2 Completed
NCT02129101 2019-10-30
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Mayo Clinic
Phase 1 Completed
NCT00037817 2019-09-30
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00260832 2019-09-11
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Eisai Inc.
Phase 3 Completed
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed